PTC Therapeutics (NASDAQ: PTCT) insider files Form 144 for share sale
Rhea-AI Filing Summary
PTC Therapeutics insider Neil G. Almstead filed a Form 144 to potentially sell 1,026 shares of common stock through Fidelity Brokerage Services on NASDAQ around 01/07/2026. The filing notes that these shares were acquired on 01/05/2026 through restricted stock vesting from the issuer as compensation.
As context, the company had 80,288,305 common shares outstanding. Over the prior three months, Neil G. Almstead reported selling 35,572 shares for gross proceeds of 2,852,153.65 on 11/24/2025, 71,928 shares for 6,001,524.59 on 11/25/2025, and 1,279 shares for 98,415.98 on 01/06/2026. Zheng Y. Almstead reported selling 54 shares for 4,155.17 on 01/06/2026.
Positive
- None.
Negative
- None.
FAQ
What does this Form 144 filing for PTCT disclose?
The filing discloses that Neil G. Almstead plans a potential sale of 1,026 shares of PTC Therapeutics common stock through Fidelity Brokerage Services LLC on NASDAQ, with an approximate sale date of 01/07/2026.
How many PTCT shares is Neil G. Almstead planning to sell?
The notice covers a proposed sale of 1,026 shares of PTC Therapeutics common stock in a single transaction routed through Fidelity Brokerage Services LLC.
How did Neil G. Almstead acquire the PTCT shares being sold?
The 1,026 shares to be sold were acquired on 01/05/2026 via restricted stock vesting from the issuer, with the nature of payment listed as compensation.
What recent PTCT stock sales by Neil G. Almstead are reported?
In the past three months, Neil G. Almstead reported selling 35,572 shares for 2,852,153.65 on 11/24/2025, 71,928 shares for 6,001,524.59 on 11/25/2025, and 1,279 shares for 98,415.98 on 01/06/2026.
Were there other related PTCT insider sales disclosed in this Form 144?
Yes. The filing shows that Zheng Y. Almstead, at the same address, sold 54 shares of common stock on 01/06/2026 for gross proceeds of 4,155.17.
How many PTCT shares were outstanding at the time of this notice?
The Form 144 lists 80,288,305 shares of common stock outstanding for PTC Therapeutics.